Fabrinet Director Makes a Strategic Stock Move

Fabrinet Director Darlene S. Knight sold 500 shares worth $236,000 on December 4, 2025. CEO Seamus Grady also sold 22.5K shares for $10M. Barclays raised Fabrinet’s price target due to strong Q1 performance and optimistic Q2 guidance. Q1 revenues hit $978M, up 22% YoY. Despite some challenges, Q2 outlook remains positive. TipRanks’ AI Analyst rates FN as Outperform, citing strong financials and positive earnings call.

Certain Common Stock of Guardant Health, Inc. are subject to a Lock-Up Agreement Ending on 5-DEC-2025.

Guardant Health, Inc.'s common stock is subject to a lock-up agreement ending on December 5, 2025. The lock-up period lasts 31 days, from November 4 to December 5, 2025. During this time, directors and executive officers cannot sell or transfer shares without consent from Goldman Sachs & Co. LLC and Jefferies LLC, with specified exceptions.

Dir Knight Sells 500 ($236K) Of Fabrinet [FN]

Knight Darlene S Director of Fabrinet [FN] filed a Form 4 on December 4, 2025 with the Securities and Exchange Commission disclosing the following changes in ownership:Date12/4/25TransactionSaleShares500Price$472.00Value$236,000Ending Holdings: 3,184 - DirectFor a free trial, or to learn more about our insider trading analysis and data services, please visit or contact us at (301) 913-5100 or send an email to info@washingtonservice.com.Founded in 1970, The Washington Service provides securities professionals with financial, economic and public policy research and data.

Fabrinet Director Darlene S. Knight Reports Sale of Common Shares

Darlene S. Knight, a Director at Fabrinet Co. Ltd., has reported the sale of common shares of the company. The information was published via EDGAR by the U.S. Securities and Exchange Commission on December 4, 2025. This news brief was generated by Public Technologies using AI and is for informational purposes only.

Argan | 10-Q: FY2026 Q3 Revenue Misses Estimate at USD 251.15 M